12 / 21
Page 58
allied
academies
Microbiology: Current Research 2017 | Volume 1, Issue 2
Joint Conference
GLOBAL APPLIED MICROBIOLOGY CONFERENCE
MICROBIAL & BIOCHEMICAL RESEARCH AND TECHNOLOGIES
October 18-19, 2017
Toronto, Canada
International Congress on
&
Background:
Rabies is 100% fatal, but it is preventable. More
than 95% of human rabies cases occur in improperly treated
individuals. This is partly because of modern post-exposure
rabies prophylaxis is expensive and therefore not readily
available in many endemic regions. Nervous tissue vaccine
has been in use for more than 100 years. These vaccines have
now been superseded in purity, potency, immunogenicity
and safety.
Objective:
The objective of this research is to evaluate the
efficacy and immunogenicity of inactivated tissue culture
rabies vaccine produced in Ethiopia.
Methods:
Twelve experimental dogs from local breed were
duly conditioned during a quarantine period and assigned
to two groups randomly. Animals in group I (cases) were
vaccinated subcutaneously with 1 ml of our experimental
vaccine. Dogs in group II served as non-vaccinated controls.
The immune response of each dog was monitored for 120
days. On the day 120 after final sampling, all dogs were
challenged in the masseter muscle with a rabies street
virus of canine origin. To evaluate the titer of the rabies
virus, neutralizing antibodies (VNA), sera were analyzed
by Fluorescent Antibody Virus Neutralization (FAVN) Test.
Geometric Mean Titers (GMT) to rabies virus was determined
at days 7, 15, 21, 30, 60, 90 and 120.
Results:
Geometric mean titers were equal to 1.59, 1.73,
2.19, 3.58, 3.17, 3.35 and 3.56 IU/ml at days 7, 15, 21, 30,
60, 90 and 120 respectively. All dogs showed VNA titers
higher than the 0.5 IU/ml mandated WHO recommended
threshold. 83.3% vaccinated dogs, survived the challenge
virus. In contrast, all dogs in the control (non-vaccinated
group), developed rabies.
Conclusions:
This study indicated cell culture-based anti-
rabies vaccine manufactured at EPHI is efficacious and
immunogenic. Field trials should be conducted before mass
vaccination of dogs to control rabies cases.
e:
ayoade.olugbenga1@gmail.comAntibody response of dogs to ETHIORAB rabies vaccine
B Hurisa
1
, A Mengesha
1
, H Lemma
1
, D Nigussie
1
, A Godana
1
, A Adhanom
1
, G Kebede
1
, S Kerga
1
, B Newayesilasie
1
, G Gebrewold
1
, D Bankovskiy
2
, A Metlin
3
,
A Kebede
1
and
K Urga
1
1
Ethiopian Public Health Institute, Ethiopia
2
Pokrov Plant of Biologics, Russia
3
Institut Pasteur, Cambodia